Investor Insights

This summary was created by AI, based on 3 opinions in the last 12 months.

According to the experts, the stock XBI-N has recently broken down and has been in the $80-90 range with strong free cash flow, making it a good diversification option away from tech. One expert is bullish about healthcare and recommends buying at $83 while selling the $90 September calls to collect $3.25. Overall, there are mixed opinions about the stock's performance and potential.

Fair Value

Biotechs look speculative in profitability. She prefers big pharma, seeing continued value, despite big moves in stocks.


Healthcare has been an ignored sector, but is enjoying some momentum and will do well in second-half 2024. McKesson, Merck and Amgen, all holdings in this ETF, are doing well and even making new highs. Also, biotech does well when rates come down.


Bought it last year, and just sold it. This stock has broken down.


XBI has been in the $80-90 range. Has strong free cash flow. A good way to diversify away from tech. You can sell calls against it.


She's very bullish healthcare. Buy it at $83. She's selling the $90 September calls, collecting $3.25.

Owning a biotech ETF like XBI is fine for risk management. Healthcare is recession-resistant and he loves it.
Many biotech companies are trading below their cash levels. He doesn't own the stocks, but is good with ETFs like this. He expects more M&A in biotechs as big pharma buys these companies.
options He normally won't buy an ETF, but someone bought 20,000 of the May 95 strike calls for a little over $1.00. It's a very diverse diverse biotech ETF.
Exposure to the covid vaccine is quite minimal in this ETF. Very short term over-bought and he expects a 10-15% correction. Trim some exposure into strength. Longer term, the biotech sector looks good.

The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.


(A Top Pick October 10/17 Up 0.2%) He stepped out of this a month after they recommended it. It broke down on the relative strength measure and has not done much else since. He likes the healthcare space still however.


This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.


He likes biotech. This ETF will be an equal weight of all the names, so you are going to get some of the smaller cap names, which will have benefited you. Thinks there is lots of growth left in this space.


Biotechs have a strong seasonality that starts in July, so right about now you should get a nice move. It has a historical 100% gain potential in July. Believes that healthcare and biotech specifically is probably the next thing that is going to move the needle for humanity, so he would accumulate this on a long-term basis. Owning this for 10 years will be a good thing.

Showing 1 to 14 of 14 entries
  • «
  • 1
  • »

Spdr S&P Biotech Etf(XBI-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 4

Stockchase rating for Spdr S&P Biotech Etf is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Spdr S&P Biotech Etf(XBI-N) Frequently Asked Questions

What is Spdr S&P Biotech Etf stock symbol?

Spdr S&P Biotech Etf is a American stock, trading under the symbol XBI-N on the NYSE Arca (XBI). It is usually referred to as AMEX:XBI or XBI-N

Is Spdr S&P Biotech Etf a buy or a sell?

In the last year, 4 stock analysts published opinions about XBI-N. 2 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Spdr S&P Biotech Etf.

Is Spdr S&P Biotech Etf a good investment or a top pick?

Spdr S&P Biotech Etf was recommended as a Top Pick by on . Read the latest stock experts ratings for Spdr S&P Biotech Etf.

Why is Spdr S&P Biotech Etf stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Spdr S&P Biotech Etf worth watching?

4 stock analysts on Stockchase covered Spdr S&P Biotech Etf In the last year. It is a trending stock that is worth watching.

What is Spdr S&P Biotech Etf stock price?

On 2024-07-23, Spdr S&P Biotech Etf (XBI-N) stock closed at a price of $99.76.